Dec 12, 2017




Clinical Hub,Tools & Resources,UWHC Lab Test Directory,Molecular Diagnostics

JAK2 Mutation V617F, Qualitative, PCR, Bone Marrow

JAK2 Mutation V617F, Qualitative, PCR, Bone Marrow (HCJAK2BM) Molecular Diagnostics Lab Test

Name: JAK2 Mutation V617F, Qualitative, PCR, Bone Marrow

Test Name: JAK2 Mutation V617F, Qualitative, PCR, Bone Marrow

Health Link Test Code: HCJAK2BM

LIS Test Code: HCJAK2BM - code 5034

CPT Code(s): 81270

Methodology: Real-Time PCR followed by Melting Point Analysis

Days Performed: Once a week.

In-Lab Turnaround Time: 10 days.

Stat In-Lab Turnaround Time: Not available stat.

Specimen: Bone marrow aspirate

Collection Container: Lavender top

Collection Instructions:

This test should be requested at time of collection by filling out bone marrow request form UWH#HEMATOREQ.

Collection Volume: 4 mL

Pediatric Collection Volume: 2 mL

Stability Ambient:

24 hours

Stability Refridgerated:

10 days

Stability Frozen:

Not acceptable

Sample Analyzed: Bone Marrow Aspirate

Testing Volume: 2 mL

Pediatric Testing Volume: 1.2 mL

Specimen Processing:

Do not centrifuge sample.

Specimen Transport:

Transport specimen to laboratory immediately. Refrigerate specimen if not delivered immediately. Do not freeze sample.


Not detected

Interpretation Type: Expected Results

Test Limitations:

Detection range is 2.5% allele burden and above.

Additional Information:

For Bone Marrow samples in which the Jak2 V617F allele is detected a qualitative value of "Detected" will be reported. If the Jak2 V617F allele burden is not detected or detected below detection range of 2.5% a result of "Not Detected" will be reported.


 A result of 'Not detected" does not rule out the presence of the Jak2 V617F allele. False negative results may be due to inhibitory substances that may be present in the specimen. Inadequate specimen collection, processing and storage may invalidate test results. This test should not be used as the only criterion to form a clinical conclusion. Instead, results should be correlated with other test results, patient symptoms and clinical presentation.


The performance characteristics of this test were validated by UWHC Clinical Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The UWHC Clinical Laboratories is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.


A written interpretive report is provided by the laboratory.


A professional fee is associated with this test.